Refine your search

Search Results within category "Skin Conditions"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
13 Study Matches

An Open-Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

Atopic Dermatitis (AD): Topical Cream, Pediatrics 2-17 years old with active AD. This is a 4 week study with a follow up 1 month after the end of treatment.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT03257644
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Mild Atopic Dermatitis (AD) severity
Parent or legal guardian consent
Exclusion Criteria:
History of Hep B, Hep C, or HIV
AD only on hands or feet
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site For AbbVie- HS Surgery

Site For AbbVie- HS Surgery
Logan Claar at lclaar@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be able to travel to Hershey Medical Center for 12 visits
Must be diagnosed with HS for 1 year prior to study participation
Must be willing to perform self injections at home
Exclusion Criteria:
Prior treatment of Humira or other biologics for the treatment of HS
Skin Conditions
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa: Phase 2 Subject and Investigator Blinded, 68 week study with phone call 20 weeks after last dose. Hidradenitis Suppurativa (HS) is a chronic recurrent and debilitating skin condition that typically presents with deep and painful lesions. The most common areas affected are the armpits, the groin, and the anus and genitals area. The purpose of the study is to find out if risankizumab is beneficial and well tolerated in patients with HS. Each subject will be assigned to 1 of 3 treatment groups, reassigned to a different treatment at week 16, and then receive risankizumab at week 20.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03926169
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Moderate to Severe HS for at least 1 year
HS lesions in at least 2 affected areas
Willing to follow all study instructions
Exclusion Criteria:
Certain treatments for HS are not allowed; coordinator will discuss specific treatments
unable or unwilling to return to the study site for all study visits and tests.
Known Hepatitis B, Hepatitis C, or HIV infections
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy, and Safety Study in Prurigo Nodularis with Nalbuphine ER Tables for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)

Prurigo Nodularis: Phase 2b/3 Subject and Investigator Blinded, 56 Week study. Oral medication taken twice daily, Males/Females 18 years and older with Prurigo Nodularis Prurigo Nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules) to form on the skin. The itching (pruritus) can be intense, cause people to scratch themselves to the point of bleeding or pain. The goal of this study is to evaluate the change of itch with using Nalbuphine ER.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03497975
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
PN involving 2 affected areas
Willing to follow all study directions and attend appointments
Exclusion Criteria:
PN affecting only 1 part of the body
Certain diagnosis associated with PN are not allowed, coordinator will discuss specifics
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Evaluating perceptions of teledermatology for people with Hidradenitis Suppurativa.

We would like to assess patient perceptions regarding willingness to use teledermatology services for people with hidradenitis suppurativa (HS).
Melissa Butt at mbutt1@pennstatehealth.psu.edu or 717-531-6117
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years of age or older
Diagnosed with Hidradenitis Suppurativa
Can read and write in English
Access to the internet
Exclusion Criteria:
Less than 18 years old
No diagnosis of HS
No access to internet
Skin Conditions
  Email this study information to me
  Contact the study team

Dermatomyositis: A patient’s perspective on living with the disease

Survey study and focus group to assess health anxiety and indirect costs for patients with dermatomyositis.
Melissa Butt at mbutt1@pennstatehealth.psu.edu or 717-531-6117
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18 years or older
Diagnosis of Dermatomyositis
Patient of Penn State Health
Exclusion Criteria:
A concurrent cancer dianosis (expect basal or squamous cell cancer)
Skin Conditions
  Email this study information to me
  Contact the study team

A randomized, subject and investigator blinded, placebocontrolled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa

Hidradenitis Suppurativa: Phase 2 Subject and Investigator Blinded, 7 and a half month study. Platform Study: Injectable and Oral drug, Males/Females 18-65 years old with Hidradenitis Suppurativa. Hidradenitis Suppurativa (HS) is a chronic recurrent and debilitating skin condition that typically presents with deep and painful lesions. The most common areas affected are the armpits, the groin, and the anus and genitals area. The purpose of the study is to find out if the study drugs (iscalimab and LYS006) are beneficial and safe in patients with HS.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03827798
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
HS diagnosis for at least 1 year
HS lesions in at least 2 affected areas
Exclusion Criteria:
Prior treatment to certain medications
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate ti Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa: Phase 2 Double-Blind, 12 week placebo controlled period followed by 24 week active treatment period. Oral Medication, Males/Females 18 years and older with Hidradenitis Suppurativa. Hidradenitis Suppurativa (HS) is a chronic recurrent and debilitating skin condition that typically presents with deep and painful lesions. The most common areas affected are the armpits, the groin, and the anus and genitals area. The purpose of this study is to see if Avacopan is safe and effective for the treatment of HS.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03852472
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
HS diagnosis for at least 6 months
HS lesions in at least 2 affected areas
Willing to follow all study instructions
Exclusion Criteria:
Certain treatments for HS are not allowed; coordinator will discuss specific treatments
Positive test result for HIV, Hep C or Hep B
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Defining the cellular and molecular signatures that are associated with the clinical heterogeneity of hidradenitis suppurativa

Patients with the clinical diagnosis of mild, moderate to severe Hidradenditis Suppurativa or normal healthy volunteers ages 18 and older to participate in a 1 time study visit. There is no treatment provided but we may gain information for the treatment of HS.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-1513
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years and older
Hidradentitis Suppurativa diagnosis for 3 months
Normal skin participants
Exclusion Criteria:
Patients who are Pregnant
Normal skin participants do not have an autoimmune disease
Participants who do not want to have any of the lesion sampling performed
Skin Conditions
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Associations of dietary preferences with management of HS symptoms

We will be examining the diets of people with hidradenitis suppurativa to see if they consume different amounts of foods like dairy, tomatoes, or gluten.
Melissa Butt at mbutt1@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
People who have a history of hidradenitis suppurativa
Seen at Penn State Health within the past year
18 years of age or older
Can read/write in English
Have access to the internet
Exclusion Criteria:
Those who do not meet inclusion criteria
Skin Conditions, Food & Nutrition
  Email this study information to me
  Contact the study team

Site For PaTH Study for HS Outcome Measures

Site For PaTH Study for HS Outcome Measures
Melissa Butt at mbutt1@pennstatehealth.psu.edu or 717-531-6117
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
patients with Hidradenitis suppurativa
must be 18 years or older
fluent in English
Exclusion Criteria:
cannot read or speak English
under 18 years of age
do not have Hidradenitis suppurativa
Skin Conditions
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Assessing hair care practices in pediatric patients

Examining the differences/trends in hair care maintenance for all ethic type in the treatment of seborrheic dermatitis.
Melissa Butt at mbutt1@pennstatehealth.psu.edu or 717-531-6117
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 18 years of age or older
Parent of at least 1 child under the age of 18
Access to the Internet
Exclusion Criteria:
All children are over the age of 18
Skin Conditions
  Email this study information to me
  Contact the study team

Site for An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadaticinib in Pediatric Subjects with Severe Atopic Dermatitis

Phase 1, multiple-dose, open-label study consisting of two parts, male and female subjects aged 2 to 12 years with severe atopic dermatitis (eczema).
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT03646604
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
must weight 22 pounds or more
Have a diagnosis of Atopic Dermatitis for at least 6 months
Exclusion Criteria:
Certain treatments are not allowed; coordinator will discuss specific treatments
No active Hep A, Hep C or Hep B
Current participation in another clinical trial
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA